Literature DB >> 12695174

Methotrexate is the leading DMARD in Finland.

T Klaukka, K Kaarela.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695174      PMCID: PMC1754541          DOI: 10.1136/ard.62.5.494

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  6 in total

1.  Impact of tight control strategy on rheumatoid arthritis in Sarawak.

Authors:  Cheng Lay Teh; Jin Shyan Wong
Journal:  Clin Rheumatol       Date:  2010-10-01       Impact factor: 2.980

2.  The 2010 ACR/EULAR classification criteria for rheumatoid arthritis in the Heinola inception cohort--diagnoses confirmed by long-term follow-up.

Authors:  Kalevi Kaarela; Jenni E Kauppi; Markku J Kauppi
Journal:  Clin Rheumatol       Date:  2011-11-04       Impact factor: 2.980

3.  Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study.

Authors:  P L C M van Riel; A J Taggart; J Sany; M Gaubitz; H W Nab; R Pedersen; B Freundlich; D MacPeek
Journal:  Ann Rheum Dis       Date:  2006-02-07       Impact factor: 19.103

4.  The pattern and clinical manifestations of rheumatoid arthritis in Sarawak General Hospital.

Authors:  C L Teh; J S Wong
Journal:  Clin Rheumatol       Date:  2008-09-05       Impact factor: 2.980

Review 5.  Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs.

Authors:  Tuulikki Sokka; Minja Envalds; Theodore Pincus
Journal:  Mod Rheumatol       Date:  2008-04-25       Impact factor: 3.023

6.  Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States.

Authors:  T Sokka; T Pincus
Journal:  Rheumatology (Oxford)       Date:  2008-08-07       Impact factor: 7.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.